10/15/2012 | PP | Biovest International raises $708,440 through one-month note financing
|
3/30/2012 | PP | Biovest International to sell $5 million of units via public offering
|
11/17/2010 | DD | Accentia, Biovest subsidiary emerge from Chapter 11 bankruptcy
|
11/2/2010 | DD | Accentia, Biovest debtor expect to emerge from bankruptcy on Nov. 17
|
10/25/2010 | DD | Accentia Biovest debtor granted final approval of $8 million DIP loan
|
10/14/2010 | DD | Accentia Biovest debtor granted interim access to $8 million DIP loan
|
10/7/2010 | DD | Accentia Biovest debtor seeks $1.11 million DIP facility advance
|
8/26/2010 | DD | Accentia Biovest debtor granted $250,000 DIP financing advance
|
8/20/2010 | DD | Accentia, Biovest report July results; Accentia stock quoted on OTCQB
|
7/26/2010 | DD | Accentia subsidiary vaccine granted orphan drug status; stock listed
|
5/14/2010 | DD | Accentia subsidiary debtor Biovest files plan, eyes summer emergence
|
10/31/2008 | PP | New Issue: Biovest wraps $300,000 tranche of $5 million 15% convertible debentures sale
|
9/26/2008 | PP | New Issue: Biovest concludes $1.15 million tranche of $5 million 15% convertible debentures sale
|
4/19/2007 | PP | Biovest gets waiver on default events connected to $7.8 million note
|
1/19/2007 | PP | Biovest ups number of warrants issued in $2 million note deal
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/26/2006 | BT | Biovest terminates NCI agreement, expands into Eastern Europe
|
9/11/2006 | BTPP | New Issue: Biovest closes $2 million placement of note with warrants
|
7/31/2006 | BT | Biovest gets positive opinion on orphan-drug mark for lymphoma drug
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/18/2006 | BT | Biovest approved to expand BiovaxID trial for non-Hodgkin's lymphoma in Russia
|
6/7/2006 | BT | Biovest reports 95% of patients trated with BiovaxID still alive after 9.2 years
|
6/6/2006 | BT | Biovest to expand phase 3 trial of BiovaxID in Ukraine and Russia
|
5/16/2006 | BT | FDA approves secondary endpoint in Biovest's phase 3 trial of BiovaxID in non-Hodgkin's lymphoma
|
5/10/2006 | BT | Biovest's AutovaxID cleared for commercial sale
|
4/6/2006 | BTPP | New Issue: Biovest settles $7.8 million private placement of notes with warrants
|
1/24/2006 | BT | Biovest's anti-cancer vaccine yields 89% survival in patients with lymphoma after 3.8 years
|